Mantel Cell Lymphoma Efficacy of Rituximab Maintenance

NCT00921414 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

299

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Rituximab
OTHER: Watch and wait

Sponsor

French Innovative Leukemia Organisation

Collaborators

[object Object]